Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
about
Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy.Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.The CYP19A1 rs3751592 variant confers susceptibility to Alzheimer disease in the Chinese Han populationThe rs4646 and rs12592697 Polymorphisms in CYP19A1 Are Associated with Disease Progression among Patients with Breast Cancer from Different Racial/Ethnic Backgrounds.Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Cancer Treatment and Bone Health.Osteoporosis and musculoskeletal complications related to therapy of breast cancerGermline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trialA comprehensive overview on osteoporosis and its risk factors
P2860
Q35661622-D80F3775-385E-434F-9741-F32DB89CFBC4Q35842073-81178B86-4907-43C3-8EE2-342587C3A036Q36578211-1D05761C-CA8D-4239-BA61-B501C4B33356Q36606068-4EAB0C02-3E27-47D8-B628-BBBD64E99425Q36688742-2F4DE9AA-C15D-41BD-8752-A084DC4D0971Q36728379-6AB85F29-410A-4E33-BAF9-F22E722BE0D1Q37226412-116A315E-F027-486F-B0D9-56713FA1861EQ37463634-9BA94305-FF3F-470C-B47D-F8A5D4F08632Q38737784-507036BC-66B1-41DC-93B7-1012C106AF2AQ38739248-2CB4F8BF-DD79-4610-8015-C5799DBFB2A3Q38739527-2B4D796B-63BF-4B2E-AA56-3D259F3D57FFQ38851505-F3E87D3F-95AC-4EF4-BE7F-B93D6B48D3D9Q49211720-A7A5CECE-9FC1-40F1-8D06-8C889580C494Q57108686-5A33CD37-B128-44D3-8792-B922C3776FEAQ57561023-7E7AC58F-C9BC-406B-A551-A5E38E028F4BQ59125691-3C8572C1-DE51-416B-9067-C793749F5BAA
P2860
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genetic polymorphism at Val80 ...... women with ER + breast cancer.
@en
Genetic polymorphism at Val80
@nl
type
label
Genetic polymorphism at Val80 ...... women with ER + breast cancer.
@en
Genetic polymorphism at Val80
@nl
prefLabel
Genetic polymorphism at Val80 ...... women with ER + breast cancer.
@en
Genetic polymorphism at Val80
@nl
P2093
P2860
P1433
P1476
Genetic polymorphism at Val80 ...... women with ER + breast cancer.
@en
P2093
Antonella Rastelli
Cheryl Mueller
Clifford Qualls
Cynthia Ma
Gerard Moskowitz
Jayasree Yarramaneni
Matthew Ellis
Reina Armamento-Villareal
Swapna Vattikutti
Tusar Giri
P2860
P304
P356
10.1016/J.BONE.2013.04.021
P577
2013-05-01T00:00:00Z